Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Capell

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Circulation|June 21, 2017
A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) InitiativeConnie N Hess, Lars Norgren, Gary M Ansel, et al.
Kidney360|May 4, 2026
Thyroid Function with Continuous KRT: A Prospective StudyMatthew Kennis, David Madison, North Foulon, et al.
American Heart Journal|May 15, 2018
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)Warren H Capell, Marc P Bonaca, Mark R Nehler, et al.
Annals of the Rheumatic Diseases|August 19, 2005
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial dataJ A P Da Silva, J W G Jacobs, J R Kirwan, et al.
Journal of the American College of Cardiology|August 21, 2024
Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity RevascularizationMario Enrico Canonico, Cecilia C Low Wang, Judith Hsia, et al.
Rheumatology (Oxford, England)|October 18, 2000
The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trialD L Scott, H Berry, H Capell, et al.
Circulation|May 6, 2024
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PADJustin T Morrison, Mario Enrico Canonico, Sonia S Anand, et al.
JACC. Advances|May 13, 2025
Preserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials: Insights From MARINERShea E Hogan, Mario Enrico Canonico, Robert W King, et al.
Journal of the American College of Cardiology|May 19, 2021
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD TrialRupert M Bauersachs, Michael Szarek, Marianne Brodmann, et al.
Circulation. Cardiovascular Interventions|February 27, 2026
Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD TrialMario Enrico Canonico, Jessica Parr, E Sebastian Debus, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Circulation|June 21, 2017
A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) InitiativeConnie N Hess, Lars Norgren, Gary M Ansel, et al.
Kidney360|May 4, 2026
Thyroid Function with Continuous KRT: A Prospective StudyMatthew Kennis, David Madison, North Foulon, et al.
American Heart Journal|May 15, 2018
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)Warren H Capell, Marc P Bonaca, Mark R Nehler, et al.
Annals of the Rheumatic Diseases|August 19, 2005
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial dataJ A P Da Silva, J W G Jacobs, J R Kirwan, et al.
Journal of the American College of Cardiology|August 21, 2024
Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity RevascularizationMario Enrico Canonico, Cecilia C Low Wang, Judith Hsia, et al.
Rheumatology (Oxford, England)|October 18, 2000
The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trialD L Scott, H Berry, H Capell, et al.
Circulation|May 6, 2024
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PADJustin T Morrison, Mario Enrico Canonico, Sonia S Anand, et al.
JACC. Advances|May 13, 2025
Preserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials: Insights From MARINERShea E Hogan, Mario Enrico Canonico, Robert W King, et al.
Journal of the American College of Cardiology|May 19, 2021
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD TrialRupert M Bauersachs, Michael Szarek, Marianne Brodmann, et al.
Circulation. Cardiovascular Interventions|February 27, 2026
Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD TrialMario Enrico Canonico, Jessica Parr, E Sebastian Debus, et al.
Pageof 8